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ABSTRACT

Computational Modeling of Protein Dynamics with GROMACS and Java
By Miaoer Yu

GROMACS is a widely used package in molecular dynamics simulations of
biological molecules such as proteins, and nucleic acids, etc. However, it requires many
steps to run such simulations from the terminal window. This could be a challenge for
those with minimum amount of computer skills. Although GROMACS provides some
tools to perform the standard analysis such as density calculation, atomic fluctuation
calculation, it does not have tools to give us information on the specific areas such as
rigidity that could predict the property of the molecules. In this project, I have developed
a user friendly program to carry out molecular dynamics simulations for proteins using
GROMACS with an easy user input method. My program also allows one to analyze the
rigidity of the proteins to get its property.
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1. Introduction to Molecular Dynamics Simulation
Molecular dynamic simulation is a computational method that simulates the motion
of a system of particles. McCammon introduced the first protein simulations in 1977, and
since then this method has been widely used in the theoretical study of biological
molecules including proteins and nucleic acids because it can provide molecular change
information by calculating the time dependent behavior of a molecular system [1, 2]. For
example, GROMACS is a package that carries out molecular dynamic simulations, and
generates a trajectory of the molecule. GROMACS’s high performance draws a lot of
interest from researchers looking to develop their own tools to analyze the GROMACS
trajectories. JGromacs, one of many applications written in the different languages from
that used by GROMACS, analyzes the trajectories generated by GROMACS. JGromacs
does not work with large molecules due to its huge memory consumption. In our project,
we attempt to simplify the GROMACS steps, and develop our own analysis tool that
works well with large molecules.
The goal of a molecular dynamics simulation is to predict macroscopic properties
such as pressure, energy, heat capacities, etc. from the microscopic properties including
atomic positions and velocities generated by molecular dynamic simulations. The bridge
between macroscopic properties and microscopic properties is statistical mechanics using
the time independent statistical average [1]. A molecular dynamics simulation generates a
sequence of points in a multidimensional space as a function of time, where the points
belong to the same collection of all possible systems which have different mechanical
states such as positions or coordinates, and have the same thermodynamic state such as
temperature, volume, pressure [1].
In statistical mechanics, an ensemble averages corresponding to experimental
observables, and this means the molecular dynamics simulations must calculate all
possible states of the system to get the ensemble averages [1]. “The Ergodic hypothesis,
which states that the time average equals the ensemble average,” allows the molecular
dynamics simulation with enough representative conformations to calculate information
on macroscopic properties using a feasible amount of computer resources [1].
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In terms of classical mechanics, the molecular dynamics simulation is based on
Newton’s equation of motion:
Fi = miai

(1.1)

where Fi is the force acts on the particle, mi is the particle mass and ai is its acceleration.
The force is also equal to the gradient of the potential energy:
Fi = -dV / dri

(1.2)

where V is the potential energy of the system. The acceleration can be expressed as:
ai = d2ri / dt2

(1.3)

From equation 1.1, 1.2 and 1.3, we can relate the derivative of the potential energy to the
changes in position as a time function:
-dV / dri = miai = mi (d2ri / dt2)

(1.4)

When the acceleration, a, is constant:
a = dv / dt

(1.5)

v = at + v0

(1.6)

v = dx /dt

(1.7)

From the combination of 1.5, 1.6 and 1.7, we obtain the relation of x and the acceleration,
a, the initial position, x0, and initial velocity, v0 at time t:
x = at2 + v0t + x0

(1.8)

From equation 1.4, the acceleration is the derivative of the potential energy with respect
to the position, r:
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a = (-dE/dr) / m

(1.9)

We can obtain the initial positions of the atoms from experimental structures, such as
the x-ray crystal structure of the molecule, the acceleration from the gradient of the
potential energy function, and the initial distribution of velocities from:
N

P = ∑mivi = 0

(1.10)

i=1

where P is momentum, vi is the velocities that are often chosen randomly from a
Maxwell-Boltzmann or Gaussian distribution at a given temperature [1].
The potential energy is a function of the atomic positions of all the atoms in the
system. Because this function is complicated, it must be solved numerically with
numerical algorithms such as Verlet algorithm, Leap-frog algorithm, Velocity Verlet,
Beeman’s algorithm, etc [1].
In [1], those algorithms are introduced. “All of those algorithms assume the positions,
velocities and accelerations can be approximated by a Taylor series expansion:
r(t + δt) = r(t) + v(t)δ
δt + (1/2)a(t) δt
δ2+…

(1.11)

v(t + δt) = v(t) + a(t)δ
δt + (1/2)b(t) δt
δ 2+…

(1.12)

a(t + δt) = a(t) + b(t)δ
δt + …

(1.13)

where r is the position, v is the velocity, a is the acceleration, etc.”
For example, to derive the Verlet algorithm, we can write:
r(t + δt) = r(t) + v(t)δ
δt + (1/2)a(t)δ
δt2

(1.14)

r(t - δt) = r(t) - v(t)δ
δt + (1/2)a(t)δ
δt2

(1.15)

Combining 1.14 and 1.15, we obtain:
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r(t + δt) = 2r(t) – r(t – δt) + a(t)δ
δt2

(1.16)

This algorithm uses positions and acceleration at time t and the positions from time t
– δt to calculate the new positions at time t + δt.
The available potential energy functions such as the AMBER, CHARMM,
GROMOS, OPLS / AMBER, etc. provide reasonably good accuracy with reasonably
good computational efficiency [1]. Therefore, we have the needed information to
calculate the trajectory that describes the positions, velocities and acceleration of the
particles at different time, and we can determine the detailed information about the
molecules [1].
In general, there are three stages in molecular dynamics simulation: preparation of the
input, production molecular dynamics, and analysis of the result (Figure 1) [3].
Stage I: Preparation
This stage has multiple steps including generating the topology file; defining a box
and filling it with solvent, and adding any counter-ions to neutralize the system;
performing energy minimization to provide stable simulation; performing equilibration
for sufficient time to get stable pressure, temperature and energy [3].

Stage II: Production
This stage is the longest stage resulting in a trajectory containing coordinates and
velocities of the system.

Stage III: Analysis
The last stage includes analysis of the resulting trajectory and data files to obtain
information on the property of the molecule. Some important quantities calculated in this
stage include RMS difference between two structures, RMS fluctuations, and rigidity or
constant force, etc. The equations used to calculate those quantities are listed as the
following [1, 4]:
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RMS difference between two structures
RMSD = <(riα – riβ )2>1/2 = ((1/Ni) ∑ (riα – riβ )2)1/2
i

(1.17)

RMS fluctuations
RMSF = ((1/Nf) ∑ (rif – riavg)2)1/2
F

(1.18)

Rigidity or force constant, ki, where i represents amino acid in a protein:
ki = 3KBT / <(di - <di>)2>

(1.19)

where KB is Boltzmann coefficient, T is temperature in the simulation, di is the average
distance of Cαi from other Cαi in the protein excluding Cαs of the immediate neighbors,
and <di> is the same as di but averaged over the entire simulation [4].
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Stage I

Generate Topology

Define Box and Solvate

Add Ions

Energy Minimization

Equilibration

Stage II

Production MD

Stage III

Analysis

Figure 1. Three stages in molecular dynamic simulation: preparation of the input, production
molecular dynamic and analysis of the result.

Among many molecular dynamics simulation packages, GROMACS, CHARMM,
AMBER, and NAMD are most commonly used [5]. We will use GROMACS in our study
because it is open-source, and popular in the study of protein. Before we develop a tool to
analyze the GROMACS data, we need to understand GROMACS. In the next section, we
will introduce GROMACS and its features.
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2. GROMOCS Overview
GROMACS is an acronym for GROningen Machine for Chemical Simulation. It was
developed at the University of Groningen, The Netherlands, in the early 1990s [6]. This
open-source project is written in ANSI C, and contains about 100 utility and analysis
programs which allow users to perform molecular simulations and energy minimization
(EM) for biological molecules [6]. It is one of the most commonly used molecular
dynamics simulation packages. The following is a list of the main features the
GROMACS has [7, 8].
1. Features for generating topologies and coordinates [7, 8]
pdb2gmx – converts pdb files to topology and coordinate files.
editconf – edits the box and writes subgroups
genbox – solvates a system
genion – generates mono atomic ions on energetically favorable positions

2. Features for running a simulation [7, 8]
grompp – makes a run input file
mdrun – performs a simulation, does a normal mode analysis or an EM.

3. Features for processing properties [7, 8]
g_energy – writes energies to xvg files and displays averages
g_gyrate – calculates the radius of gyration
g_potential – calculates the electrostatic potential across the box
g_density – calculates the density of the system

4. Features for processing files [7, 8]
trjconv – converts and manipulates trajectory files

5. Analysis tools [7, 8]
g_rms – calculates rmsd’s with a reference structure and rmsd matrices
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g_rmsf – calculates atomic fluctuations

The typical GROMACS MD run of the protein such as lysozyme is demonstrated in
the flow chart (Figure 2) [7, 8]. In the flow chart, the steps are listed in the left column,
while the highlighted GROMACS tools are listed in the right column corresponded to the
left column.
To learn how to use GROMACS in MD of the protein, we followed the tutorial for
lysozyme [9]. In this example, PDB file 1AKI.pdb can be downloaded from RCSB
website for hen egg white lysozyme (PDB code 1AKI). The pdb2gmx generates a
topology for the molecule, the position restraint file, and a post-processed structure file.
The lysozyme is simulated in a simple aqueous system. The editconf tool defines the
box dimensions, and the genbox tool fills the box with water. The purpose of the genbox
is to keep track of the number of added water molecules, and update the topology with
the changes [7, 8]. Now the system is solvated and contains a charged protein.
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The tool grompp (GROMACS pre-processor) processes the ions.mdp (molecular
dynamics parameter file), the coordinate file and topology to generate an atomic-level
input (ions.tpr) containing all the parameters for all of the atoms in the system. The
genion tool reads through the topology and replaces water molecules with the ions
specified by the user to neutralize the net charges on the protein [9].
The energy minimization relaxes the structure to ensure that the system has no steric
clashes or inappropriate geometry [9]. The tool grompp assembles the minim.mdp, the
structure, topology to generate an input file (em.tpr), and then the tool mdrun runs the
energy minimization to generate an energy-minimized structure file em.gro, energy file
em.edr and trajectory em.trr. The analysis of em.edr file with the tool g_energy results in
the following graph showing the steady convergence of Epotential (Figure 3) [9].

Figure 3. Energy Minimization for Lysozyme (1AKI).
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Once we get the reasonable starting structure, we need to equilibrate the solvent and
ions around the protein under an NVT ensemble (the constant Number of particles,
Volume, and Temperature) and an NPT ensemble (the constant Number of particles,
Pressure, and Temperature) [9]. The same tools used in EM step perform the two-phase
equilibration. The tool g_energy processes the result to generate plots for NVT (Figure 4)
and NPT (Figure 5) [9].

Figure 4. Temperature for Lysozyme (1AKI).

Figure 4 shows that the system reaches the target temperature, and stays there over
the remainder of the equilibration. Figure 5 has the fluctuated pressure value. However,
the running average of these data is stable [9].
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After finishing the preparation stage, the previous tools grompp and mdrun are used
to perform the production MD to generate the final trajectory file md.trr and md.xtc etc.

Figure 5. Pressure for Lysozyme (1AKI).

After finishing the simulation, we can analyze the system with GROMACS tools
trjconv, g_rms, g_rmsf, etc. The RMSD plot obtained with the tool g_rms (Figure 6)
shows that the structure is very stable with stable RMSD. The RMSF plot obtained with
the tool g_rmsf (Figure 7) shows how each residue fluctuates during the period of the
production run [9].

18

Figure 6. RMSD for Lysozyme (1AKI)

Figure 7. RMS Fluctuation for Lysozyme (1AKI).
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As shown in Figure 2, there are many steps involved in the whole process of
molecular dynamics simulation. Some users may find it difficult to use the GROMACS
from a terminal window. On the other hand, GROMACS provides some tools to perform
the basic analysis of the trajectories, but we could not find tools to give us the
information on the specific areas such as rigidity we are interested in due to its relation to
the protein property [4]. In the next section, we will show the development of a Java
program that simplifies the GROMACS steps through GUIs and processes the trajectories
to give rigidity information of the protein.
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3. Java Program Design and Implementation
The two goals in this project are to simplify the MD running steps in GROMACS
with GUIs, and to create an analysis tool that processes the GROMACS trajectories and
gives us the rigidity profile of the proteins.
GROMACS is written in the C language, but we will develop our program in Java.
Therefore, we investigated two methods that allow Java to use the codes and code
libraries written in other languages such as C. One involves the Java Native Interface
(JNI), and another involves Java Runtime class. The former requires six steps to call C
from Java code [10]:
1. Create the Java code. The code needs to have declaration of the native method,
load the shared library containing the native code, and then call the native
method.
2. Compile the Java code
3. Create the C header file by running javah –jnj command on the java code
4. Create the C code
5. Compile the C code and create shared library
6. Execute Java program.

The latter involves creating an object of Runtime, and this Runtime object calls the
Runtime method exec(command) where the command can be used to call C functions.
Some codes related to the script call in Runtime are as follows:
Runtime rt = Runtime.getRuntime();

//create an object rt of Runtime

String[] cmds = {scriptName, parm1, parm2};
Process process = rt.exec(cmds);
process.waitFor();

//command to execute the script

//create a process object

//wait for the script completion

Since the former is more complicated to implement, we use the latter in our program.
We built the GUIs with the Model-View-Controller (MVC) pattern first described by
Krasner and Pope for building user interfaces in Smalltalk-80 [11]. In MVC, the model
contains data and some tasks, the view presents the data to the user, and the controller
updates the model as necessary when the user interacts with the view [12]. The separation
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of the three components makes it easy to reuse and maintain the codes. In our program,
we combine the view and the controller in the same class, but separate the data from the
presentation. Due to its large library, containing lots of reusable codes, we wrote the
program in Java, and have our Model to extend the java class Observable that provides
the register/notify infrastructure needed to support the views implementing the java
interface Observer [12]. When the view sees a user interaction, the listeners registered by
the controller are called, and then the controller calls the mutator methods of the model to
update its state, and the model calls setChanged() and notifyObservers() after it has
changed the state. NotifyObservers() will notify the registered observer that the change
has been made, and the observer containing the required update method will make the
change to itself [12].
The class diagram of the project is illustrated in Figure 8. Our program consists of
three subpackages including task, data and gui. The task package contains the classes for
distance calculation, rigidity calculation and the regular file processing; the data package
contains the classes that represent the binary structural data such as the trajectory file,
structure file, etc. and the gui package contains the different view/controller classes that
allow users to enter their settings for the simulations, and the model class that stores the
user inputs.
The program communicates with the users for their inputs starting with
MainPanelView class. The MainPanel view is illustrated in Figure 9.
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Figure 8. UML class diagram of the project.
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Figure 9. Initial panel view.

Six function buttons including “Home”, “Preparation”, “Production Run”, “Auto
Run”, “Plot”, and “Exit” are listed on the left column of the page, and the help function
button is in the upper left corner. The user can select the specific function by clicking on
the button labeled with the name of the function. After the user selects the function, the
corresponding page will be displayed for the user inputs.
When the user clicks on Home, Figure 9 is displayed. The user enters the MD folder,
and the program later will store the files created during the MD preparation and
production.
When the user clicks on Preparation, the Preparation page will be displayed for the
required and optional files and parameters (Figure 10). The user can either provide the
pdb file or the PDB code of the protein. If the user gives both, the pdb file will be used.
Four mdp files including ions mdp, EM mdp, NVT mdp and NPT mdp are required in
this stage. If the user does not specify the file paths, we will use the default files
contained in the package.
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Figure 10. PreparationView panel.

When the user clicks on Production run, the MD Production page will be displayed
for the required and optional files and parameters (Figure 11). If the user does not provide
the file paths, we will use the default MD mdp contained in the package, and the NPT gro
file, topology resulting from the preparation stage in the MD folder, and default options
and output tpr file name.

Figure 11. ProductionView panel.
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When the user clicks on Analysis, the analysis page will display three basic analysis
tools (Figure 12). If the user clicks on RMSD, RMSF, or Rigidity, the corresponding tool
page will be displayed under the analysis page (Figure 13, Figure 14, and Figure 15).

Figure 12. AnalysisView panel.

Figure 13. RMSDView panel.

The RMSD view also displays the default options, and the output xvg file name.
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Figure 14. RMSFView panel with default output xvg file name.

Figure 15. RigidityView Panel.

The rigidity view allows the users to choose the region of the protein they want to
study, or/and the frames they want to consider since the frames at the beginning of the
simulation are not stable and could be ignored. If the users don’t provide any input, we
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will use the default mdp file, the NPT gro file, and the trajectory file resulting from the
previous MD run.

Figure 16. PlotView panel.

When the user clicks on the Plot button, the user is asked to input the data file, and
the program displays the requested rigidity profile plot labeling the amino acids with high
rigidity (Figure 16). If the user wants to take the default settings, he/she can click on the
Auto Run button, and then enter the pdb file or pdb code on the corresponding page. The
program will run the steps included in preparation and production stages with the default
settings. The user can exit the program by clicking the exit button.
To simplify the MD process, we prepared scripts that execute the MD steps (see
Attached CD). After the user enters the input or takes the default values, and then clicks
on the submit button, the program will run the scripts in Java Runtime. It is crucial to
realize that although GROMACS is written in the C language, Java Runtime class allows
users to conduct their GROMACS research in a Java environment. In this way, the user
does not need to exit the program to have a MD run in another environment.
The second goal of this project is to process the trajectories to get the rigidity profile
of the protein. As mentioned before, we use Boltzmann coefficient and the distance of the
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backbone carbon (Cα) of the protein from other backbone carbons (Cαs) in the protein in
the calculation of the rigidity.
We need to obtain the coordinate information from the binary structural data file
containing the trajectories, and then use the information to calculate the rigidity of the
protein. The resulting rigidity profile can be used to describe the mechanical properties of
the protein.
There are many packages, such as Biojava, StatAlign, Jmol and JGromacs, written in
Java for bioinformatics analysis [5]. Among those packages, JGromacs has a much
smaller API because it is designed to focus on the specific functionalities such as
analyzing GROMACS trajectories [5]. We thought we would find the right tool for
reading the GROMACS trajectory file to get the coordinate information of the alpha
carbons. However, it has very low performance when it processes the large trajectory file
of the large protein. We successfully used JGromacs to process the trajectory file of
lysozyme that has 129 amino acids. However, when we ran the simulation with longer
proteins that are more than 600 residues long, the computer took much longer, and the
resulting trajectory file is much larger.
JGromacs parses the trajectory file via the use of GROMACS tool gmxdump with
Java Runtime class. What the gmxdump does is to read a trajectory file and print that to
standard output in a readable format [7]. JGromacs calls the gmxdump function and reads
the information from the standard output, and then stores the information in memory. In
general, MD simulations of proteins generate a huge trajectory file. When we incorporate
JGromacs in our package, the machine is very slow with a small protein or hangs with a
large protein. We cannot use JGROMACS in our program due to its low performance in
input/output (IO) caused by huge memory consumption.
To get the coordinates of the alpha carbons of the protein, we must find an efficient
way to read the trajectory file. The file with trr file extension contains the trajectory of a
simulation. All the coordinates, velocities, forces and energies are printed as specified in
the mdp file. The trr file in GROMACS contains many frames of data, and each frame
has the same data structure as follows [7]:
int magic; // magic number
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int sLen; // the String version length
int linefeed; // line feed
String version = ""; // version
int ir_size; // Backward compatibility
int e_size; // Backward compatibility
int box_size; // Non zero if a box is present
int vir_size; // Backward compatibility
int pres_size; // Backward compatibility
int top_size; // Backward compatibility
int sym_size; // Backward compatibility
int x_size; // Non zero if coordinates are present
int v_size; // Non zero if velocities are present
int f_size; // Non zero if forces are present
int natoms; // The total number of atoms
int step; // Current step number
int nre; // Backward compatibility
float t; // Current time
float lambda; // Current value of lambda
float [][] box;
float [][] vir;
float [][] pres;
float [][] coordinates;
float [][] velocities;
float [][] forces;

From the MD mdp file, we can calculate the total number of frames stored in the
trajectory file with formula:
Total number of frames = nsteps / nstxout + 1
where nsteps and nstxout are the parameters found in the MD mdp file. With Java API,
we can easily get the size of the trr file in bytes, and hence a frame in bytes. Therefore,
we can know the offset of each frame in the file. The offset, the data structure of the
frame, and the alpha carbon index obtained from the NPT gro file allow us to get the
coordinate information of the alpha carbons.
To solve the memory consumption problem found in JGromacs, we load one frame of
information to the buffer at a time, extract the coordinate data of the alpha carbons, and
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then store the coordinates in an array. In this way, the size of the data we process is very
small. Hence, the performance is increased.
To compare the performance between the JGROMACS and our method in getting the
coordinate information, we wrote a small program to get the information from a
trajectory file with JGROMACS’s strategy since we can not directly use JGROMACS
due to its exception with large protein. The following table demonstrates the performance
of two methods on getting the coordinates of the alpha carbons from a trr file of size 13G
resulting from the 10 ns molecule dynamics simulation of PCSK9 protein (Table 1).

Table 1: Comparison of two methods

Time (second)

JGROMACS Method

MYGromacs Method

5008

102

The result indicates our method increases the performance about 50 times.
In summary, we improve the performance by two strategies: to divide the large
amount of structural data into frames of data and process one frame of data at a time; and
to limit the number of objects created for each entry in the trajectory file by storing the
information in an array. The codes are documented in the attached CD.
In the next section, we will demonstrate the rigidity profile of the lysozyme and
compare its property with the RMS fluctuation property obtained from the GROMACS
tool. After we confirm the reliability of our program with the well studied lysozyme, we
will perform the similar study on the PCSK9 compounds that play important roles in
cholesterol metabolism.
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4. Applications
I. PCSK9 Introduction
Cholesterol is an important component of cellular membranes and is a precursor of
steroid hormones and bile acids. It has been extensively studied due to its strong
correlation with blood and heart diseases. Both dietary cholesterol and that are
synthesized de novo are transported by the circulation in lipoproteins [13]. Familial
hypercholesterolemia (FH) is a genetic hyperlipidermia that is characterized by high
levels of plasma cholesterol carried by low-density lipoprotein (LDL) [14]. LDL is the
main cholesterol transport protein in plasma, and the endocytosis of cholesterol-rich LDL
can be mediated by LDL receptor (LDLr) [14]. FH is most commonly caused by
mutations in the gene encoding the LDLr. It is also caused by mutations in three more
genes encoding Apoprotein B-100, ARH adapter protein, and PCSK9 protease [14].

Figure 17. The four proteins associated with familial hypercholesterolemia. LDLr forms a complex with
Apoprotein B-100 surrounding a cholesterol ester core. In the presence of ARH adapter protein, the
complex enters the cell by the endocytosis of the coated pit. Adapted from Nussbaum et al [14].

As shown in Figure 17, in the process of cholesterol uptake by the LDLr, a
cholesterol ester core is surrounded by apoprotein B-100 to form a protein moiety of
LDL. The mature LDLr binds the moiety, travels to the coated pits, and then enters the
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cell by endocytosis of the coated pits in the presence of ARH adaptor protein. Once it
enters the cell, LDL is hydrolyzed to release free cholesterol. Therefore, mutations in the
genes encoding LDLr, Apoprotein B-100, PCSK9 and ARH adaptor protein can affect
the cholesterol uptake by the LDLr [11]. The removal of LDL cholesterol from
circulation can be reduced by mutation of LDLr, impairing LDL-LDLr binding caused by
mutations in apoprotein B-100, or impairing the internalization of the LDL-LDLr
complex caused by mutations in the ARH protein, or degradation of the LDLr caused by
the mutations in PCSK9 [14].
According to Nussbaum et al, “the LDLr is a transmembrane glycoprotein mainly
expressed in the liver and adrenal cortex, and plays a key role in cholesterol homeostasis.
Hepatic LDLr clears about 50% of intermediate-density lipoproteins (IDL) and 66% to
80% of LDL from the circulation by endocytosis [14]”. It is worth the effort of studying
the LDLr since elevated plasma LDL levels cause atherosclerosis.
2% ~ 10% LDLr mutations are large insertions, deletion, or rearrangement mediated
by recombination between Alu repeats within LDLr [14]. These mutations decrease the
efficiency of IDL and LDL endocytosis, resulting increasing production of LDL from
IDL, and decreasing hepatic clearance of LDL. Therefore, the clearance of LDL through
LDLr-independent pathways is increased, resulting in atherosclerosis [14]. The effect of
LDL receptor mutations on LDL plasma levels depends on environment, gender, and
genetic background. Diet is the major environment modifier of LDL plasma levels
because dietary cholesterol suppresses the synthesis of LDL receptors and thereby raises
plasma LDL levels [14].
It has been reported that a mutation in PCSK9 is involved in autosomal dominant
hypercholesterolemia (ADH), a rare form of FH without mutations of LDLr and the
ligand binding domain of apoprotein B-100 [15].
PCSK9 has cytogenetic location: 1p32.3 and molecular location on chromosome 1:
base pairs 55,505,148 to 55,530,525 [16]. An enzyme encoded by the PCSK9 gene in
humans has orthologs found across many species. Increased PCSK9 protease activity
causes the degradation of LDL receptor, thereby lowers the level of the receptor in
hepatocytes, and regulates the LDL cholesterol metabolism [15]. Gain-of-function
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missense mutations in the gene encoding PCSK9 enhance the activity of the PCSK9
protein, and cause FH. Loss-of-function mutations in the PCSK9 gene lead to an increase
in the number of LDLr on the surface of liver cells. Hence, the amount of cholesterol
circulating in the bloodstream is lowered [15]. As shown in Figure 18, in the cell PCSK9
interacts with LDLr for degradation through two pathways. In the first pathway, PCSK9
is secreted from cells, and then the extracellular PCSK9 internalized with the LDLr [15].
Bottomeley and coworkers studied the interaction of PCSK9 with LDLr, and found that
PCSK9 binds LDLr at the first epidermal growth factor-like repeat homology domain
(EGF-A) of LDLr [17]. Mutations in EGF-A inhibit the degradation of LDLr. It is also
been found that PCSK9 dimers were more effective than PCSK9 monomer in degrading
LDLr, and acidic endosomal pH increases the binding of PCSK9 with LDLr [15].

Figure 18. Two Pathway of PCSK9. Adapted from G. Lambert et al [15].

In the second pathway, PCSK9 acts on the LDLr after its biosynthesis before it reaches
the basolateral surface of the cell [15].
PCSK9 is one of many secreted proteins that are essential for the regulation of
biological activity are initially synthesized as inactive precursor proteins and are
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subsequently proteolytically converted in the secretory pathway to the mature active
forms [18]. These proteinases are called subtilisin-like proprotein convertases (SPCs) or
protein convertases (PCs) because they have subtilisin-like catalytic domain [18]. Protein
convertases are divided into S8A and S8B subfamilies. S8B contains seven closely
related core members including subtilisin/kexin PCSK1, PCSK2, furin, PCSK4, PCSK5,
PCSK6, PCSK7, while S8A contains more distantly related endoproteinases SKI-1/S1P,
PCSK9 [19]. The pro-PCs contain multi domains including a signal peptide, a catalytic
domain, a pro-domain, P-domain, a cysteine-rich domain, transmembrane domain and
cytosolic domain. Each domain has its unique function. The signal peptide directs
translocation into endoplasmic reticulum (ER); the pro-domain has intramolecular
chaperone functions that direct compartment-specific activation, assist in folding of
molecules, disassociate after the second internal cleavage event, and may autoinhibit PCs
in select circumstances; the catalytic domain that contains the conserved catalytic triad
that consists of asparate, histidine and serine; the P-domain may stabilize acidic
prodomain and catalytic domain, and is required for catalytic activity; a cysteine-rich
domain confers protein-protein interaction properties, and directs cell-surface tethering;
the transmembrane domain and cytosolic domain direct PC sorting and transit control
within cell compartments. Transmembrance and cytosolic domains are present only in
furin, PCSK5, PCSK6, PCSK7 [19].
Proprotein convertases activate a broad range of distinct proteins. PCSK1 and PCSK2
activate polypeptide prohormones; Furin activates multiple mammalian and microbial
precursor proteins; PCSK4 activates proteins involved in sperm motility, reproduction;
PCSK5 and PCSK6 activate ECM proteins; PCSK7 activates multiple precursors; SKI1/S1P processes membrane-bound transcription factors involved in lipid metabolism; and
PCSK9 regulates plasma LDL levels through increased degradation of LDLr proteins
[19]. Physiologically important proteins may require activation by means of posttranslational cleavage of an inactive precursor molecule. The deficiency of PCSK1 or
PCSK2 results in abnormal glucose homeostasis, and impaired prohormones processing.
PCSK1, PCSK2, furin, PCSK5, PCSK6, PCSK7 have been associated with cancers
through the complex interactions among their activated substrate [19]. PCs also relate to
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infectious diseases and lipid disorders, atherosclerosis and Alzheimer’s disease, and
biodefense. Therefore, PCs are potential therapeutic targets [19].
According to Lambert et al., “PCSK9 is synthesized as a 72-kDa protein of 692
amino acids in which the signal peptide (residues 1-30) and the prodomain (residue 31 –
152) of PCSK9 precedes a catalytic domain (residues 153 – 451), that contains the
canonical D186, H226 and S386 catalytic triad as well as the oxyanion hole N317
residue, followed by a C-terminal domain (residues 452 – 692) [15]”.

Figure 19. Ribbon structure of PCSK9. Adapted from G. Lambert et al [15].

As shown in Figure 19, the prodomain consists of two α helices and a four-stranded
antiparallel β sheet. The prodomain associates with catalytic domain through
hydrophobic and electrostatic interactions [15]. PCSK9 autocatalytically cleaves the
peptide bond after non-basic amino acids between Gln152 and Ser153 to generate a 14kDa prodomain and a 63-kDa moiety [15]. The prodomain are permanently associated
with the 63 kDa PCSK9 moiety, and the four C-terminal amino acids of the prodomain
(residues 149 – 152) bind in the catalytic site and further inhibit the catalytic activity by
N-terminus extension of the prodomain [19]. The catalytic domain consists of sevenstranded parallel β sheet and α helices. The catalytic triad of PCSK9 consists of residues
Asp186, His226, and Ser386. PCSK9 does not act as a catalyst but as a chaperone that
binds the LDLr at its epidermal growth factor-like repeat A (EGF-A) for lysosomal
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degradation [15]. The V domain of PCSK9 consists of three barrel-like subdomains that
are made up of antiparallel β strands, and stabilized by three internal disulfide bonds [15].
The V domain is rich in histidine residues that can control the pH-dependent proteinprotein interactions [15].
Researchers have been studying how the mutations in PCSK9 relate to FH. They
reported the disease-associated variants in a database at www.ucl.ac.uk/ [20]. As shown
in Figure 20, the mutations of PCSK9 can be found in any domains of PCSK9.

Figure 20. Number of variants in each domain of the PCSK9 gene according to putative function (n = 73).
Intronic variants have not been included. Adapted from Leigh et al [20].

The selected naturally occurring variants are summarized in Table 2. The loss-offunction mutations include L82X, Y142X, C679X, DR97, G106R, L253F, N157K and
H391N, while the gain-of-function mutations include D374Y, D374H, S127R, D129G,
F216L, and R218S [15].
The function of PCSK9 is physiologically significant, and it is clinically relevant to
measure circulating levels of PCSK9 and to study pharmacological factors affecting its
secretion. It has been reported that plasma PCSK9 levels correlate positively with LDL
cholesterol but not with HDL cholesterol or TG in healthy donors [15]. PCSK9 has
become a validated target for the treatment of hypercholesterolemia and associated
cardiovascular diseases. Study suggests that pharmacologic interventions that inhibit
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PCSK9 may be safe. The first approach to inhibit PCSK9 include targeting PCSK9
mRNA that involves the delivery of single-stranded antisense DNA-like chimeric
oligonucleotides via an RNaseH-mediated pathway, and injection of liposomal double
stranded RNA-like siRNAs that interact with the RNA-interference silencing complex
[19, 20, 21].
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Table 2. PCSK9 naturally occurring variants (X represents stop codon) [20, 22].

Protein
p.Arg46Leu

Domain
Pro-domain

p.Leu82X

Pro-domain

p.Arg97del

Pro-domain

p.Gly106Arg

Pro-domain

p.Ser127Arg
p.Asp129Gly
p.Tyr142X

Pro-domain
Pro-domain
Pro-domain

p.Asn157Lys

Catalytic

p.Phe216Leu

Catalytic

p.Arg218Ser

Catalytic

p.Leu253Phe

Catalytic

p.Asp374Tyr

Catalytic

p.Asp374His

Catalytic

p.Cys679X

C-terminal
domain

Effect
AA type
Loss of function,
descreased
phosphorylation of Ser47 basic
Loss of function,
truncated peptide,
aliphatic
disrupt proper folding
Loss of
function,disrupts the fold
of the entire prodomain. basic
Loss of function,
improper orientation of
the beta-strands.
unique
Gain of function,
polar neutral
Gain of function
acidic
Loss of function,
truncated peptide,
aromatic
disrupt proper folding
Loss of function, could
break hydrogen bond
and then destabilize the
polar neutral
packing of this helix
Gain of function can't
undergo the second
cleavage that can't not
induce LDLr degradation. aromatic
Gain of function can't
undergo the second
cleavage that can't not
induce LDLr degradation. basic
Loss of function, results
in a PCSK9 protein that is
defective in
aliphatic
autoprocessing.
Gain of function,
increases in affinity for
LDLr by Hydrogen
bonding or pi stacking
acidic
with H306 of EGF-A.
Gain of function,
increases in affinity for
LDLr by Hydrogen
bonding or pi stacking
acidic
with H306 of EGF-A.
Loss of function,
truncated peptide,
polar neutral
disrupt proper folding

Wild
hydrophobicity

AA type

-14

aliphatic

97

X

Mutant
hydrophobicity

97

-14

0
-5
-55

basic
basic
unique

-14
-14
0

63

X

-28

basic

-23

100

aliphatic

97

-14

polar neutral

-5

97

aromatic

100

-55

aromatic

63

-55

basic

8
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X

The second approach to inhibit PCSK9 directly by molecules includes antibodies or
small interfering RNAs that interfere with PCSK9/LDLr interaction at the plasma
membrane, inhibitors of PCSK9 catalytic activity within the ER, other proprotein
convertases that enhance PCSK9 cleavage, and molecules that destabilize the PCSK9
structure to mimic loss of function mutants [19, 23]. A list of inhibitors of PCSK9
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currently undergoing development to reduce the LDL-C levels are summarized in Table 3
[24]. It has been reported that an antibody for PCSK9 (mAb1) administered to wild-type
mice doubled the hepatic content of LDLR and reduced serum total cholesterol by 36%
[24]. Cynomolgus monkeys treated with a single dose of PCSK9 siRNA had a mean
reduction in LDL-C levels of 56% [24].

Table 3: PCSK inhibitors under development [24].

Many other PCs have been studied, especially furin. Comparative study of PCSK9
with well characterized furin and other PCs will be an efficient way to get information
about PCSK9.

II. Comparative study of PCSK9 with other PCs
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Sun and coworkers reported that the multiple sequence alignment of PCSK9 with
furin and three PCs (PCSK4, PCSK5 and PCSK6) using Clustal2 shows that PCSK9 is
closely resemble to furin [25]. When they compared the key residues in the binding
pocket of furin and those in PCSK9, they found that the obtained multiple sequence
alignment indicated the mutations of PCSK9 including N192 → S, R193 → -, E230 →
Q, V231 → G, E257 → -, A267 → L, S319 → G, S343S → L, P372 → A.
The 3D structure of the furin catalytic domain with an inhibitor complex (Protein
Data Bank ID: IP8J) was created with Chimera 1.6 (Figure 21) [26].

Figure 21. Furin Binding Pocket. Adapted from Sun, et al [25].

The sensitivity and the compensatory effect of the positive charge at substrate
positions P4-P6 requires negatively charged residues in the binding pocket of PCs [25].
Negatively charged residues at position 230 and 257 play a key role in regulation of the
substrate specificity of mammalian proprotein convertases since they interact with a
positively charged residue at substrate position P5 or P6, and facilitate flexible
interactions in this region [25]. It has been reported that cleavage of proprotein
convertases can be inhibited by a small molecule characterized by positively charged
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residues at substrate position P1, P2, and P4 [25]. This small molecule dec-RVKR-cmk
efficiently binds to all seven 8B proprotein convertases [25]. This methodology can be
used to study the substrate specificity of PCSK9 and find its small molecule inhibitor.
MEGA is used to build a phylogenetic tree for PCSK9 from different species [27].

Figure 22 shows the resulting phylogenetic tree.
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The information on PCSK9 is valuable, and can be obtained from the PDB website
http://www.rcsb.org/pdb/home/home.do. Table 4 summarizes a list of solved structures of
PCSK9 [28].

Table 4: Solved PCSK9 Structure in PDB
PDB ID

Structure Title

2NP9

Crystal structure of a dioxygenase in the Crotonase superfamily

2P4E

Crystal Structure of PCSK9

2PMW
2QTW

The Crystal Structure of Proprotein convertase subtilisin kexin type 9 (PCSK9)
The Crystal Structure of PCSK9 at 1.9 Angstroms Resolution Reveals structural homology
to Resistin within the C-terminal domain

2W2M

WT PCSK9-DELTAC BOUND TO WT EGF-A OF LDLR

2W2N

WT PCSK9-DELTAC BOUND TO EGF-A H306Y MUTANT OF LDLR

2W2O

PCSK9-DELTAC D374Y MUTANT BOUND TO WT EGF-A OF LDLR

2W2P

PCSK9-DELTAC D374A MUTANT BOUND TO WT EGF-A OF LDLR

2W2Q

PCSK9-DELTAC D374H MUTANT BOUND TO WT EGF-A OF LDLR

2XTJ

THE CRYSTAL STRUCTURE OF PCSK9 IN COMPLEX WITH 1D05 FAB

3BPS

PCSK9:EGF-A complex

3GCW

PCSK9:EGFA(H306Y)

3GCX

PCSK9:EGFA (pH 7.4)

3H42

Crystal structure of PCSK9 in complex with Fab from LDLR competitive antibody

3M0C

The X-ray Crystal Structure of PCSK9 in Complex with the LDL receptor

3P5B

3P5C

The structure of the LDLR/PCSK9 complex reveals the receptor in an extended
conformation
The structure of the LDLR/PCSK9 complex reveals the receptor in an extended
conformation
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Although the number of solved structures is limited, it may take researchers weeks or
months to build the model from the x-ray experimental data. When the molecule becomes
larger and larger, the disadvantage of the experimental method becomes obvious. The
molecular dynamics simulation could be a reasonable method for the study of PCSK9.
III. Molecular Dynamic Simulation Results
We have performed MD on lysozyme (1AKI), and analyzed the trajectory with
GROMACS tool g_rmsf to get its fluctuation information, and with our program to get
the rigidity profile (Figure 23).

Figure 23. Fluctuation and rigidity profile of the Lysozyme (1AKI). The simulation is 5 ns MD run with
GROMACS.
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Figure 23 represents the fluctuation and rigidity profile of lysozyme. As seen on the
figure, the residues with high fluctuation often have low rigidity. For example, the strong
rigidity peak is located in the #50 – #55 region where fluctuation is small. This result
confirms our program can correctly predict the rigidity of the residues. We plotted the
rigidity data with our program (Figure 24).We also labeled the predicted high rigidity
residues including Trp28, Ala32, Phe38, Thr40, Ile55, Ser91, and Ala95 in Chimera
image of lysozyme (Figure 25) [29].

Figure 24. Rigidity profile plotted with our program.
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Figure 25. Residues with high rigidity predicted by our program are Trp28, Ala32, Phe38, Thr40,
Ile55, Ser91, and Ala95. These residues are labeled with 1 letter code and shown in sphere shapes in the
Chimera image of lysozyme (1AKI).

Our program allows the users to easily locate the amino acid residues with high
rigidity by labeling those amino acids above the threshold value set by the user (the
default value is 50% of the maximum value). Both fluctuation and rigidity information
would help us to understand the property of the biological molecule. It has been found
that three amino acid positions beneath the active site are occupied by Thr 40, Ile 55, and
Ser 91 in hen, pheasant, and other avian lysozymes [30] with experimental methods.
These three amino acids can be found among the amino acids with high rigidity predicted
by our program.
The above result on lysozyme indicates our program could be used in the study of
other proteins such PCSK9. We performed the similar study on PCSK9 (PDB code:
2P4E) (Figure 26). Since PCSK9 is a bigger protein with some missing residues in the
initial configuration, we will focus on analyzing the region (#219 – #449) with the
longest unbroken sequence (Figure 27). Within this region, L286, T313, V336, A363,
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T385, A389 and V392 are predicted to have high rigidity, and there is no reporting
mutation among them [20]. The result indicates the rigidity profile could predict the
conserved region of the protein.

Figure 26. PCSK9 (1AKI) rigidity profile with missing residues located in the disconnected region in the
graph. The simulation is 10 ns MD run with GROMACS.
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Figure 27. The fluctuation and rigidity profile of PCSK9 partial sequence (#219 - #449).

It has been reported that D374 is the binding location where the PCSK9 forms the
complex with LDLr, and its mutations change its binding efficiency with LDLr [17].
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Figure 27 indicates D374 has high fluctuation and low rigidity result. We also labeled the
predicted high rigidity residues including L286, T313, V336, A363, T385, A389, and
V392 in Chimera image of PCSK9 (Figure 28) [29].

Figure 28. Residues with high rigidity predicted by our program are L286, T313, V336, A363, T385,
A389, and V392. These residues are labeled with 1 letter code and shown in sphere shapes and located in
the center of the A chain in the Chimera image of PCSK9 (2P4E). The triad residues located on the left of
the center, and D374 are also labeled.

We need more analysis on the pattern of the fluctuation and rigidity on other residues
to find the important information about the binding of the PCSK9 and the LDLr.
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5. Conclusions
In this project, we learned how to use GROMACS in molecule dynamics simulations.
Through the molecule dynamics simulation of lysozyme using GROMACS, we
understood that the process of running GROMACS in protein dynamics simulations
involves many steps, and GROMACS does not provide a tool to analyze the rigidity of
the protein.
We have developed a Java application to simplify the steps involved in GROMACS.
We investigated two methods that allow us to call C code from Java, and we decided to
use Java Runtime class method since JNI method is too complicated to implement.
Through the graphical user interface (GUI), users can easily carry out molecular
dynamics simulations using GROMACS with their own settings or simply accepting the
default settings given by the program. Our program also allows users to analyze the
GROMACS trajectories to generate the rigidity of the protein, and then plot the rigidity
profile graph with our built-in plotting feature. Compared to JGromacs, our program has
better performance, and works well with the large trajectory files.
We tested our program with lysozyme, and obtained promising results that show the
amino acids involved in the active site of the lysozyme are among the amino acids with
high rigidity. We also used our program in the molecular dynamics simulation of PCSK9,
and found that the amino acids with high rigidity are not among the amino acids that have
reported mutations. These results indicate our program could be used to find the active
site and the conserved amino acids in the protein.
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6. Future Work
A possible extension of this work would be to continue validating the program with
well studied lysozyme and its variants. This would enable us to find a method to
determine the relationship between the simulation results and the protein property, which
would allow us to expand our study to PCSK9 and its complexes with LDLr to determine
its role in cholesterol metabolism.
Another extension would be to develop a web application of this program that would
allow remote users to access the program.
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